Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Asimov logo — Intelligent design of living systems

Asimov

Intelligent design of living systems

Founded 2017 United States Boston, United States 120 employees Series B Total: $204.70M AI, Biotechnology +1

General Information

Company Name Asimov
Founded Year 2017
Location United States Boston, United States
Founders / Decision Makers
Team member Team member
Employees 120
Industries AI, Biotechnology, Health and Wellness
Funding Stage Series B
Business Model B2B, SaaS, Platform
Revenue Model Licensing, Service Fee, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Asimov. To contact Asimov, visit asimov.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Asimov compare?

A PDF of Asimov and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Asimov soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Nov 02, 2026

Asimov VP Sybil Danby will lead two panel discussions at the Biomanufacturing World Summit.

Major Customer Win Oct 22, 2026

LG Chem has chosen to adopt Asimov's CHO Edge System for therapeutic biologics.

Asimov a competitor of yours? Have our desk watch it

About Asimov

Asimov is at the forefront of bioengineering, propelling the AI, Biotechnology, and Health and Wellness industries with its innovative approach to cellular programming. Founded in 2017, the company harnesses the synergies of mammalian synthetic biology, computer-aided design, and machine learning. This unique blend aims to revolutionize the design and manufacturing processes for biologics and gene therapies.

Headquartered in the United States, Asimov recently secured a substantial $175.00M Series B investment on 01 January 2023. This financial milestone was backed by a cohort of notable investors, including CPP Investments, Pillar, Casdin Capital, KdT Ventures, Andreessen Horowitz/a16z, Horizons Ventures, and Fidelity Investments. Such robust support from reputable investors underscores the company's potential and the confidence stakeholders have in its vision.

Business keywords: Intelligent Design, Living Systems, Synthetic Biology, Mammalian Biology, Computer-Aided Design, Biologics Manufacturing, Gene Therapies, Cell Programming, Biotech Innovation, Bioengineering, Life Sciences, Cell Engineering

Services & Products

end-to-end genetic design platform
cell line development
gene and RNA therapy production
biological tools and computational models
lab-in-the-loop platform
design and manufacturing integration

Target Customers

biotech companies pharmaceutical companies synthetic biologists research institutions healthcare innovators biotherapeutics developers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $175.00M 7
CPP Investments Pillar Casdin Capital
CPP Investments, Pillar +5
01 Jan 2023
Series A $25.00M 1
Horizons Ventures
Horizons Ventures
01 Dec 2019
Seed $4.70M 1
DCVC
DCVC
01 Dec 2017
Spinout Undisclosed 2
Massachusetts Institute of Technology, Boston University
01 Jan 2017

Asimov Alternatives & Competitors

View All Alternatives
Asimov vs
Affini-T Therapeutics
Affini-T Therapeutics United States

Right Targets. Right Cells. Right Place. Unlocking the power of T cells against oncogenic driver mut...

Venture round
11 employees
Biotechnology, Health Care
Compare Asimov vs Affini-T Therapeutics
Asimov vs
Refuge Biotechnologies
Refuge Biotechnologies United States

DESIGNING INTELLIGENT CELL THERAPIES TO FIGHT CANCER

Series B
3 employees
Biotechnology, Health Care
Compare Asimov vs Refuge Biotechnologies
Asimov vs
GRO Biosciences
GRO Biosciences United States

GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein...

Series B
32 employees
Biotechnology, Health Care
Also compare with: Asimov vs Think Bioscience Think Bioscience View all alternatives

FAQ About Asimov

Intelligent design of living systems
Asimov was founded in 2017.
Asimov is headquartered in Boston, United States.
Asimov operates in AI, Biotechnology and Health and Wellness. Its work centres on Intelligent Design, Living Systems, Synthetic Biology and Mammalian Biology. Its customers include biotech companies, pharmaceutical companies and synthetic biologists.
Asimov has a B2B, SaaS and Platform business model. Its revenue comes from Licensing, Service Fee and Product Sales.
Asimov has approximately 120 employees.
Asimov has completed 4 funding rounds, raising a total of $204.70M. The latest funding stage is Series B.
Asimov offers: end-to-end genetic design platform, cell line development, gene and RNA therapy production, biological tools and computational models, lab-in-the-loop platform, design and manufacturing integration.
Top alternatives and competitors to Asimov include Affini-T Therapeutics, Refuge Biotechnologies, GRO Biosciences, Strand Therapeutics, Wheeler Bio, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Asimov and Affini-T Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Asimov, https://bouncewatch.com/company/asimov, updated 5 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout